Cadila Healthcare is trading higher by 2.5% at Rs 743 after the pharmaceuticals company said it has settled a patent litigation with US-based Warner Chilcott Company LLC.
The stock opened at Rs 735 and touched a high of Rs 749 on the National Stock Exchange (NSE). A combined 253,324 shares have changed hands on the counter till 1040 hours on the NSE and BSE.
“Cadila Healthcare and its US subsidiary Zydus Pharmaceuticals (USA) Inc have entered into an agreement in principle with Warner Chilcott Company LLC to settle all outstanding patent litigation related to Asacol HD (mesalamine) delayed-release tablets. The agreement remains subject to preparation and execution of definitive documentation,” Zydus Cadila said in a BSE filing.
Under the terms of the agreement, Warner Chilcott Company will in principle grant Cadila and Zydus a royalty-bearing license to market a generic version of its patented drug Asacol HD beginning on November 15, 2015 or earlier after Zydus gets the nod from the U.S. Food and Drug Administration (USFDA) of its Abbreviated New Drug Application (ANDA) for generic version of Asacol HD.
Alternatively, if Zydus does not receive USFDA approval of its generic version of Asacol HD by July 1, 2016, Zydus will be permitted to launch an authorized generic version of Asacol HD beginning on July 1, 2016. Other terms of the settlement were not disclosed, the company said.
The stock opened at Rs 735 and touched a high of Rs 749 on the National Stock Exchange (NSE). A combined 253,324 shares have changed hands on the counter till 1040 hours on the NSE and BSE.
“Cadila Healthcare and its US subsidiary Zydus Pharmaceuticals (USA) Inc have entered into an agreement in principle with Warner Chilcott Company LLC to settle all outstanding patent litigation related to Asacol HD (mesalamine) delayed-release tablets. The agreement remains subject to preparation and execution of definitive documentation,” Zydus Cadila said in a BSE filing.
Under the terms of the agreement, Warner Chilcott Company will in principle grant Cadila and Zydus a royalty-bearing license to market a generic version of its patented drug Asacol HD beginning on November 15, 2015 or earlier after Zydus gets the nod from the U.S. Food and Drug Administration (USFDA) of its Abbreviated New Drug Application (ANDA) for generic version of Asacol HD.
Alternatively, if Zydus does not receive USFDA approval of its generic version of Asacol HD by July 1, 2016, Zydus will be permitted to launch an authorized generic version of Asacol HD beginning on July 1, 2016. Other terms of the settlement were not disclosed, the company said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%